Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers-Reference-Cited by-同舟云学术

Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers

Published:2021-10-10 Issue:10-12 Volume:22 Page:544-553
ISSN:1538-4047
Container-title:Cancer Biology & Therapy
language:en
Short-container-title:Cancer Biology & Therapy

Author:

Weinberg David S.¹,Foster Nathan R.²,Della’Zanna Gary³,McMurray Ryan P.²,Kraft Walter K.⁴,Pallotto Angela⁴,Kastenberg David M.⁵,Katz Leo C.⁵,Henry Christopher H.⁵,Moleski Stephanie M.⁵,Limburg Paul J.²,Waldman Scott A.⁵^ORCID

Affiliation:

1. Department of Medicine, Fox Chase Cancer Center, Philadelphia, PA, USA

2. Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA

3. Division of Cancer Prevention, NCI, NIH, Bethesda, MD

4. Department of Pharmacology and Experimental Therapeutics and Division of Gastroenterology and Hepatology, Thomas Jefferson University, Philadelphia, PA, USa

5. Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USa

Funder

National Cancer Institute, Division of Cancer Prevention

Publisher

Informa UK Limited

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/15384047.2021.1967036

Reference36 articles.

1. Cancer Statistics, 2010

2. Mechanisms of action of cholera and Escherichia coli enterotoxins

3. Activation of Intestinal Guanylate Cyclase by Heat-Stable Enterotoxin of Escherichia coli: Studies of Tissue Specificity, Potential Receptors, and Intermediates

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural products from the human microbiome: an emergent frontier in organic synthesis and drug discovery;Organic & Biomolecular Chemistry;2024

2. Mechanistic and Clinical Chemoprevention;Reference Module in Biomedical Sciences;2024

3. Decoding signaling mechanisms: unraveling the targets of guanylate cyclase agonists in cardiovascular and digestive diseases;Frontiers in Pharmacology;2023-12-20

4. Guanylate cyclase-C Signaling Axis as a theragnostic target in colorectal cancer: a systematic review of literature;Frontiers in Oncology;2023-10-20

5. Challenges and opportunities in delivering oral peptides and proteins;Expert Opinion on Drug Delivery;2023-07-17